The OmniAb-Eli Lilly Deal: A Cautionary Tale of Valuation and Risk

The recent partnership between OmniAb (OABI) and Eli Lilly (LLY) has sent shockwaves through the pharmaceutical industry, with many hailing it as a game-changer for OABI. However, beneath this surface-level excitement lies a tale of two companies with vastly different financial profiles, risk tolerances, and growth strategies.

Eli Lilly’s massive commercial engine and top-line expansion dwarf OmniAb in terms of scale and profitability. In Q2 2026, Lilly generated $23 billion in revenue, while OABI reported just $13.4 million in the same quarter. Despite this enormous disparity, investors are being asked to take on significant risk by valuing OABI at a premium compared to its historical financial performance.

OmniAb’s innovative business model relies on partnerships and royalties rather than direct product sales. The company has attracted 110 active partners and 425 active programs, providing a steady stream of non-dilutive capital and downstream royalty potential through its proprietary antibody discovery platform. This high-margin licensing model is attractive to investors looking for diversification.

However, investing in OABI comes with significant risks. The company’s cash burn remains a major concern, with net losses of $5.9 million reported in Q2 2026. Milestone revenues will likely remain lumpy and unpredictable until downstream programs enter late-stage commercialization, leaving investors exposed to partner pipeline cancellations.

The partnership between OABI and Lilly may represent a growing trend towards partnerships and collaborations between small discovery engines like OABI and larger pharmaceutical companies. As development costs of new treatments continue to rise, these partnerships will become increasingly essential for both parties involved.

On the other hand, this deal can be seen as a cautionary tale about overvaluation in the absence of solid financial fundamentals. With its valuation rivaling that of more established players, OABI’s investors would do well to remember the lessons of history, where companies with similar growth profiles have ultimately fallen short.

As we watch this partnership unfold, it will be interesting to see how OABI navigates the complex web of commercial and regulatory challenges ahead. Will its innovative business model prove to be a game-changer, or will the company’s cash burn and micro-cap volatility ultimately prove to be its downfall? Only time will tell.